DALE ESSMYER: Open Payments
NPI 1770666984 · MILAN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$613 in 30 payments from 11 companies in 2025. Trend: 2023 $605 · 2024 $315 · 2025 $613
Food & beverage: $613
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $143 |
| Novo Nordisk Inc | 1 | $102 |
| Neurocrine BioSciences, Inc. | 3 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Lundbeck LLC | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| UCB, Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $15 |
Products named: Ozempic, INGREZZA, CAPLYTA, RINVOQ, REXULTI, VRAYLAR, ZORYVE, Bimzelx.
Industry payments across MO — which companies pay providers there.
